ClinicalTrials.gg
CompletedNCT03514641Updated Sep 21, 2021Results posted

An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

A Phase 2/3 interventional study of Bexagliflozin and Placebo in Essential Hypertension, sponsored by Theracos. Completed at 87 sites in United States. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-09-21.

Sponsored by Theracos · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
673
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 53 studies in Essential Hypertension with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. Essential Hypertension · United States.

Enrollment
11th of 46
673 · median 275
Started
2017
with 1 other
Phase 2/3
Only one
of the 53
Registered
36th of 53
by date

Among the 53 studies in Essential Hypertension with a site in United States, this one is the 11th largest by enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2017, is the only one in phase 2/3, and was the 36th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

8 of the 53 studies in Essential Hypertension with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Essential Hypertension with a site in United States, or all of them as a file.
02

Study summary

This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects informed of the trial design and their consent to participate in both studies were to be obtained in a single consent form. Approximately 680 male or female adult subjects were to be enrolled.

Read the detailed description

THR-1442-C-603 is an integrated assessment of the potential utility of bexagliflozin tablets, 20 mg for the treatment of essential hypertension. It is composed of two studies, 603A and 603B, measuring effects in a common population.

603A was a multicenter double-blind parallel group placebo-controlled study conducted to determine the placebo-adjusted change from baseline to week 12 in the mean ambulatory systolic blood pressure (SBP) of approximately 680 subjects considered generally representative of the adult hypertensive population in the United States. Secondary endpoints included the placebo-adjusted change from baseline to week 12 of the mean office seated systolic blood pressure, the change to week 12 of the mean ambulatory and mean office seated diastolic blood pressure, the proportion of subjects achieving prespecified goals for absolute systolic and diastolic blood pressure as well as prespecified goals for reduction in systolic and diastolic blood pressure, measured by ambulatory and seated office measurement methodology.

A603B was a multicenter double-blind parallel group placebo-controlled randomized withdrawal study conducted to determine the durability of the antihypertensive effect of bexagliflozin tablets, 20 mg, in a population not pre-selected for existing diabetes. All subjects entered a 12 week run-in period during which they self-administered open label bexagliflozin tablets, 20 mg once daily. At week 12 a baseline ambulatory blood pressure monitoring (ABPM) measurement was made, and the subjects were randomized one to one to receive either bexagliflozin tablets, 20 mg or bexagliflozin tablets, placebo. After a 12 week treatment period a second ABPM measurement was made. The primary endpoint was the intergroup difference in the change from baseline in the mean SBP.

03

Conditions studied

  • Essential Hypertension
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

To be eligible for randomization a prospective subject was to be:

  • Male or female of age ≥ 20 years
  • Diagnosed with essential hypertension and exhibiting an office seated SBP ≥ 140 and \< 180 mm Hg
  • Unmedicated or prescribed no more than 4 agents for hypertension. Unmedicated subjects were subjects who had never taken medications for hypertension or had not taken any anti-hypertensive medication for at least 3 months. A stable dose meant no change in dose or frequency had taken place in the 4 weeks prior to the screening visit
  • If female and of , willing to use an adequate method of and to not become pregnant for the duration of the study.
  • Willing and able to return for all clinic visits and to complete all study-required procedures
  • Able to self-medicate during the run-in period, omitting no more than one day of dosing
  • Shown to have a seated SBP ≥ 140 and \< 180 mm Hg
  • Shown to exhibit a mean 24 h SBP ≥ 135 mm Hg

Prospective participants exhibiting any of the following characteristics were to be excluded from the study:

  • Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young (MODY)
  • Known history of secondary or malignant hypertension
  • Seated diastolic blood pressure (DBP) >110 mm Hg at screening
  • Taking insulin for diabetes
  • Prescribed more than 4 anti-hypertension medications
  • Having a genitourinary tract infection within 6 weeks of screening or history of ≥ 3 genitourinary infections requiring treatment within the last 6 months
  • Having cancer, active or in remission for \< 3 years
  • History of alcohol or illicit drug abuse in the past 2 years
  • History of myocardial infarction, stroke or hospitalization for heart failure in the prior 6 months
  • Previous exposure to bexagliflozin or EGT0001474
  • History of hypertensive emergency
  • History of sodium glucose linked transporter 2 (SGLT2) inhibitor treatment in the last 3 months
  • Known intolerance or allergy to SGTL2 inhibitors
  • Any condition, disease, disorder, or laboratory abnormality that, in the opinion of the PI, would jeopardize the subject's appropriate participation in this study or obscure the effects of treatment
  • Pregnancy or nursing
  • Current participation in another interventional trial or having been exposed to an drug within 30 days or 7 half-lives of screening, whichever is longer
  • Arm circumference too large or small to allow accurate ambulatory monitoring
  • History of kidney transplant
  • Occupational or other lifestyle factors that could hamper the collection of valid ABPM data
  • Evidence of abnormal liver function tests (total or alkaline phosphatase > 1.5 × (ULN) with the exception of isolated Gilbert's syndrome); or (ALT) or aspartate aminotransferase (AST) > 2.5 × ULN
  • Estimated (eGFR), as calculated by the modification of diet in renal disease study equation (MDRD), \< 45 mL/min/1.73 m2 or requiring dialysis
  • > 9.5%
  • Positive urine pregnancy test for female subjects of child bearing potential
  • Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase > 1.5 × upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome); or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULN
  • eGFR, as calculated by the modification of diet in renal disease study equation (MDRD), \< 45 mL/min/1.73 m2 or requiring dialysis
  • HbA1c > 9.5%
  • Positive urine pregnancy test for female subjects of child bearing potential
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
673 participants (actual)

Study arms

  • Other
    Sequence 1

    Period 1: Placebo Period 2: Bexagliflozin Period 3: Bexagliflozin

    Drug: Bexagliflozin · Drug: Placebo

  • Other
    Sequence 2

    Period 1: Placebo Period 2: Bexagliflozin Period 3: Placebo

    Drug: Bexagliflozin · Drug: Placebo

  • Other
    Sequence 3

    Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Bexagliflozin

    Drug: Bexagliflozin

  • Other
    Sequence 4

    Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Placebo

    Drug: Bexagliflozin · Drug: Placebo

Interventions

  • Bexagliflozin tablet, 20 mg

    Also known as: EGT0001442

  • DrugPlacebo

    Placebo (inactive) tablet to match the active drug

06

What researchers measure

Primary outcomes

  1. Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12

    Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared to placebo

    Time frame: Baseline (Day 1) to week 12

  2. Change of the 24 Hour Mean Systolic Blood Pressure From Cumulative Week 24 to Week 36

    Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared placebo

    Time frame: Change from week 24 to week 36

Secondary outcomes

  1. 603A, Reduction of Mean Ambulatory Systolic Blood Pressure

    Proportion of subjects who achieve a reduction of mean ambulatory systolic blood pressure of 10 mm Hg or greater

    Time frame: Baseline (Day 1) to week 12

  2. 603A, Mean Ambulatory Systolic Blood Pressure of 135 mm Hg or Less

    Proportion of subjects who achieve a mean ambulatory systolic blood pressure of 135 mm Hg or less

    Time frame: Baseline (Day 1) to week 12

  3. 603A, Change in Seated Office Systolic Blood Pressure

    Placebo-adjusted change in seated office systolic blood pressure

    Time frame: Baseline (Day 1) to week 12

  4. 603A, Seated Office Systolic Blood Pressure of 140 mm Hg or Less

    Proportion of subjects who achieve a seated office systolic blood pressure of 140 mm Hg or less

    Time frame: Baseline (Day 1) to week 12

  5. 603A, Change in Mean Ambulatory Diastolic Blood Pressure

    Placebo-adjusted change in mean ambulatory diastolic blood pressure

    Time frame: Baseline (Day 1) to week 12

  6. 603A, Mean Ambulatory Diastolic Blood Pressure of 87 mm Hg or Less

    Proportion of subjects who achieve a mean ambulatory diastolic blood pressure of 87 mm Hg or less

    Time frame: Baseline (Day 1) to week 12

  7. 603A, Reduction of Mean Ambulatory Diastolic Blood Pressure of 4 mm Hg or Greater

    Proportion of subjects who achieve a reduction of mean ambulatory diastolic blood pressure of 4 mm Hg or greater

    Time frame: Baseline (Day 1) to week 12

  8. 603A, Change in Seated Office Diastolic Blood Pressure

    Placebo-adjusted change in seated office diastolic blood pressure

    Time frame: Baseline (Day 1) to week 12

  9. 603A, Seated Office Diastolic Blood Pressure of 90 mm Hg or Less

    Proportion of subjects who achieve a mean seated office diastolic blood pressure of 90 mm Hg or less

    Time frame: Baseline (Day 1) to week 12

  10. 603B, Change in Seated Office Systolic Blood Pressure

    Placebo-adjusted change from week 12 to week 24 in seated office systolic blood pressure

    Time frame: Week 12 (cumulative week 24) to Week 24 (cumulative week 36)

  11. 603B, Change in Mean Ambulatory Diastolic Blood Pressure

    Placebo-adjusted change in mean ambulatory diastolic blood pressure

    Time frame: Week 12 (cumulative week 24) to Week 24 (cumulative week 36)

  12. 603B, Change in Seated Office Diastolic Blood Pressure

    Placebo-adjusted change from week 12 to week 24 in seated office diastolic blood pressure

    Time frame: Week 12 (cumulative week 24) to Week 24 (cumulative week 36)

Other outcomes

  1. Integrated 603A and 603B, Effects on Mean Ambulatory Systolic and Diastolic Blood Pressure

    Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on mean ambulatory systolic and diastolic blood pressure after 12 weeks of bexagliflozin treatment, as well as longer treatment periods, i.e., 24 weeks or 36 weeks of bexagliflozin treatment.

    Time frame: Baseline (Day 1) to cumulative week 36

  2. Integrated 603A and 603B, Effects on Seated Office Systolic and Diastolic Blood Pressure

    Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on seated office systolic and diastolic blood pressure over time

    Time frame: Baseline (Day 1) to cumulative week 36

07

Results

Posted Sep 21, 2021

Participant flow

603A: 0-12 Week Study Period
Participant flow — 603A: 0-12 Week Study Period
Milestone603A: Bexagliflozin Tablets, 20 mg603A: Placebo Tablets603B: Bexagliflozin Tablets, 20 mg603B: Placebo Tablets
Started33433900
Completed30731900
Not completed272000
Withdrew: Protocol violation3300
Withdrew: Adverse event5200
Withdrew: Withdrawal by subject7500
Withdrew: Lost to follow-up10900
Withdrew: Physician decision1000
Withdrew: Lack of efficacy1000
Withdrew: 24 hr abpm not enough readings0100
603B: 24-36 Week Study Period
Participant flow — 603B: 24-36 Week Study Period
Milestone603A: Bexagliflozin Tablets, 20 mg603A: Placebo Tablets603B: Bexagliflozin Tablets, 20 mg603B: Placebo Tablets
Started00281281
Completed00267266
Not completed001415
Withdrew: Protocol violation0002
Withdrew: Adverse event0031
Withdrew: Withdrawal by subject0023
Withdrew: Lost to follow-up0066
Withdrew: 24 hr abpm not enough readings0033

Outcome measures

PrimaryChange of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12

Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared to placebo

Time frame:
Baseline (Day 1) to week 12
Reported as:
Least squares mean · mm Hg
Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12
mm HgBexagliflozin Tablets, 20 mgPlacebo Tablets
Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12-8.86 ± 0.642-6.15 ± 0.622
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.0025 · Ls means difference: -2.72 · 95% CI -4.47 to -0.96Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
PrimaryChange of the 24 Hour Mean Systolic Blood Pressure From Cumulative Week 24 to Week 36

Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared placebo

Time frame:
Change from week 24 to week 36
Reported as:
Least squares mean · mm Hg
Change of the 24 Hour Mean Systolic Blood Pressure From Cumulative Week 24 to Week 36
mm HgBexagliflozin Tablets, 20 mgPlacebo Tablets
Change of the 24 Hour Mean Systolic Blood Pressure From Cumulative Week 24 to Week 360.30 ± 0.6802.74 ± 0.678
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.0117 · Mean difference (final values): -2.43 · 95% CI -4.32 to -0.54Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
Secondary603A, Reduction of Mean Ambulatory Systolic Blood Pressure

Proportion of subjects who achieve a reduction of mean ambulatory systolic blood pressure of 10 mm Hg or greater

Time frame:
Baseline (Day 1) to week 12
Reported as:
Number · proportion of participants
603A, Reduction of Mean Ambulatory Systolic Blood Pressure
proportion of participantsBexagliflozin Tablets, 20 mgPlacebo Tablets
603A, Reduction of Mean Ambulatory Systolic Blood Pressure0.40 (0.35 to 0.46)0.34 (0.29 to 0.40)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.1317 (Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP) · Odds ratio (or): 1.30 · 95% CI 0.92 to 1.83
Secondary603A, Mean Ambulatory Systolic Blood Pressure of 135 mm Hg or Less

Proportion of subjects who achieve a mean ambulatory systolic blood pressure of 135 mm Hg or less

Time frame:
Baseline (Day 1) to week 12
Reported as:
Number · Proportion of subjects
603A, Mean Ambulatory Systolic Blood Pressure of 135 mm Hg or Less
Proportion of subjectsBexagliflozin Tablets, 20 mgPlacebo Tablets
603A, Mean Ambulatory Systolic Blood Pressure of 135 mm Hg or Less0.40 (0.34 to 0.46)0.29 (0.24 to 0.35)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.0113 · Odds ratio (or): 1.60 · 95% CI 1.11 to 2.30Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
Secondary603A, Change in Seated Office Systolic Blood Pressure

Placebo-adjusted change in seated office systolic blood pressure

Time frame:
Baseline (Day 1) to week 12
Reported as:
Least squares mean · mm Hg
603A, Change in Seated Office Systolic Blood Pressure
mm HgBexagliflozin Tablets, 20 mgPlacebo Tablets
603A, Change in Seated Office Systolic Blood Pressure-11.24 ± 0.799-6.61 ± 0.787
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = <0.0001 · Mean difference (final values): -4.63 · 95% CI -6.83 to -2.42Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
Secondary603A, Seated Office Systolic Blood Pressure of 140 mm Hg or Less

Proportion of subjects who achieve a seated office systolic blood pressure of 140 mm Hg or less

Time frame:
Baseline (Day 1) to week 12
Reported as:
Least squares mean · Proportion of subjects
603A, Seated Office Systolic Blood Pressure of 140 mm Hg or Less
Proportion of subjectsBexagliflozin Tablets, 20 mgPlacebo Tablets
603A, Seated Office Systolic Blood Pressure of 140 mm Hg or Less0.38 (0.33 to 0.44)0.25 (0.21 to 0.30)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.0004 · Odds ratio (or): 1.86 · 95% CI 1.32 to 2.62Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
Secondary603A, Change in Mean Ambulatory Diastolic Blood Pressure

Placebo-adjusted change in mean ambulatory diastolic blood pressure

Time frame:
Baseline (Day 1) to week 12
Reported as:
Least squares mean · mm Hg
603A, Change in Mean Ambulatory Diastolic Blood Pressure
mm HgBexagliflozin Tablets, 20 mgPlacebo Tablets
603A, Change in Mean Ambulatory Diastolic Blood Pressure-3.92 ± 0.349-3.08 ± 0.337
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.0863 · Mean difference (final values): -0.83 · 95% CI -1.79 to 0.12Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
Secondary603A, Mean Ambulatory Diastolic Blood Pressure of 87 mm Hg or Less

Proportion of subjects who achieve a mean ambulatory diastolic blood pressure of 87 mm Hg or less

Time frame:
Baseline (Day 1) to week 12
Reported as:
Least squares mean · Proportion of subjects
603A, Mean Ambulatory Diastolic Blood Pressure of 87 mm Hg or Less
Proportion of subjectsBexagliflozin Tablets, 20 mgPlacebo Tablets
603A, Mean Ambulatory Diastolic Blood Pressure of 87 mm Hg or Less0.47 (0.41 to 0.53)0.37 (0.32 to 0.43)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.0232 · Odds ratio (or): 1.48 · 95% CI 1.06 to 2.08Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
Secondary603A, Reduction of Mean Ambulatory Diastolic Blood Pressure of 4 mm Hg or Greater

Proportion of subjects who achieve a reduction of mean ambulatory diastolic blood pressure of 4 mm Hg or greater

Time frame:
Baseline (Day 1) to week 12
Reported as:
Least squares mean · Proportion of subjects
603A, Reduction of Mean Ambulatory Diastolic Blood Pressure of 4 mm Hg or Greater
Proportion of subjectsBexagliflozin Tablets, 20 mgPlacebo Tablets
603A, Reduction of Mean Ambulatory Diastolic Blood Pressure of 4 mm Hg or Greater0.88 (0.83 to 0.92)0.80 (0.73 to 0.85)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.0140 · Odds ratio (or): 1.81 · 95% CI 1.13 to 2.91Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
Secondary603A, Change in Seated Office Diastolic Blood Pressure

Placebo-adjusted change in seated office diastolic blood pressure

Time frame:
Baseline (Day 1) to week 12
Reported as:
Least squares mean · mm Hg
603A, Change in Seated Office Diastolic Blood Pressure
mm HgBexagliflozin Tablets, 20 mgPlacebo Tablets
603A, Change in Seated Office Diastolic Blood Pressure-4.44 ± 0.504-2.13 ± 0.496
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.0011 · Mean difference (final values): -2.31 · 95% CI -3.70 to -0.92Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
Secondary603A, Seated Office Diastolic Blood Pressure of 90 mm Hg or Less

Proportion of subjects who achieve a mean seated office diastolic blood pressure of 90 mm Hg or less

Time frame:
Baseline (Day 1) to week 12
Reported as:
Least squares mean · Proportion of subjects
603A, Seated Office Diastolic Blood Pressure of 90 mm Hg or Less
Proportion of subjectsBexagliflozin Tablets, 20 mgPlacebo Tablets
603A, Seated Office Diastolic Blood Pressure of 90 mm Hg or Less0.65 (0.59 to 0.71)0.53 (0.47 to 0.59)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.0094 · Odds ratio (or): 1.63 · 95% CI 1.13 to 2.35Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
Secondary603B, Change in Seated Office Systolic Blood Pressure

Placebo-adjusted change from week 12 to week 24 in seated office systolic blood pressure

Time frame:
Week 12 (cumulative week 24) to Week 24 (cumulative week 36)
Reported as:
Least squares mean · mm Hg
603B, Change in Seated Office Systolic Blood Pressure
mm HgBexagliflozin Tablets, 20 mgPlacebo Tablets
603B, Change in Seated Office Systolic Blood Pressure1.98 ± 0.8465.18 ± 0.859
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.0083 · Mean difference (final values): -3.20 · 95% CI -5.57 to -0.83Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
Secondary603B, Change in Mean Ambulatory Diastolic Blood Pressure

Placebo-adjusted change in mean ambulatory diastolic blood pressure

Time frame:
Week 12 (cumulative week 24) to Week 24 (cumulative week 36)
Reported as:
Least squares mean · mm Hg
603B, Change in Mean Ambulatory Diastolic Blood Pressure
mm HgBexagliflozin Tablets, 20 mgPlacebo Tablets
603B, Change in Mean Ambulatory Diastolic Blood Pressure0.10 ± 0.3690.94 ± 0.368
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.1085 · Mean difference (final values): -0.84 · 95% CI -1.87 to 0.19Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
Secondary603B, Change in Seated Office Diastolic Blood Pressure

Placebo-adjusted change from week 12 to week 24 in seated office diastolic blood pressure

Time frame:
Week 12 (cumulative week 24) to Week 24 (cumulative week 36)
Reported as:
Least squares mean · mm Hg
603B, Change in Seated Office Diastolic Blood Pressure
mm HgBexagliflozin Tablets, 20 mgPlacebo Tablets
603B, Change in Seated Office Diastolic Blood Pressure0.51 ± 0.5071.76 ± 0.514
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Covariance · p = 0.0837 · Mean difference (final values): -1.25 · 95% CI -2.67 to 0.17Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP
Other pre-specifiedIntegrated 603A and 603B, Effects on Mean Ambulatory Systolic and Diastolic Blood Pressure

Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on mean ambulatory systolic and diastolic blood pressure after 12 weeks of bexagliflozin treatment, as well as longer treatment periods, i.e., 24 weeks or 36 weeks of bexagliflozin treatment.

Time frame:
Baseline (Day 1) to cumulative week 36
Reported as:
Mean · mm Hg
Integrated 603A and 603B, Effects on Mean Ambulatory Systolic and Diastolic Blood Pressure
mm HgEffect on Mean Ambulatory SBPEffect on Mean Ambulatory DBP
12 Weeks-7.595 (-8.565 to -6.625)-3.269 (-3.773 to -2.764)
24 Weeks-9.262 (-10.559 to -7.965)-4.044 (-4.720 to -3.368)
36 Weeks-12.454 (-14.988 to -9.921)-5.566 (-6.825 to -4.308)
Other pre-specifiedIntegrated 603A and 603B, Effects on Seated Office Systolic and Diastolic Blood Pressure

Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on seated office systolic and diastolic blood pressure over time

Time frame:
Baseline (Day 1) to cumulative week 36
Reported as:
Mean · mm Hg
Integrated 603A and 603B, Effects on Seated Office Systolic and Diastolic Blood Pressure
mm HgEffect on Seated Office SBPEffect on Seated Office DBP
6 Weeks-8.43 ± 16.399-4.50 ± 9.534
12 Weeks-9.91 ± 15.777-4.10 ± 9.716
18 Weeks-14.46 ± 16.000-5.87 ± 9.282
24 Weeks-12.53 ± 18.830-4.92 ± 10.910
36 Weeks-15.71 ± 16.975-6.47 ± 9.933

Adverse events

Collected over For 603A, adverse events were collected from baseline to Week 12. For 603B, adverse events were collected from Week 24 to Week 36.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
603A: Bexagliflozin Tablets, 20 mg0/334 (0%)11/334 (3.3%)94/334 (28.1%)
603A: Placebo Tablets0/339 (0%)10/339 (2.9%)88/339 (26%)
603B: Bexagliflozin Tablets, 20 mg0/281 (0%)9/281 (3.2%)32/281 (11.4%)
603B: Placebo Tablets0/281 (0%)6/281 (2.1%)37/281 (13.2%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
Event603A: Bexagliflozin Tablets, 20 mg603A: Placebo Tablets603B: Bexagliflozin Tablets, 20 mg603B: Placebo Tablets
Atrial fibrillationCardiac disorders0/3340/3392/2810/281
OsteoarthritisMusculoskeletal and connective tissue disorders2/3340/3390/2811/281
Myocardial infarctionCardiac disorders0/3341/3390/2811/281
Necrotising fasciitisInfections and infestations0/3340/3391/2810/281
Crohn's diseaseGastrointestinal disorders0/3340/3391/2810/281
Intestinal obstructionGastrointestinal disorders0/3340/3390/2811/281
Large intestine polypGastrointestinal disorders0/3340/3391/2810/281
Muscle ruptureMusculoskeletal and connective tissue disorders0/3340/3390/2811/281
Pelvic fractureInjury, poisoning and procedural complications0/3340/3391/2810/281
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/3341/3390/2811/281
Most frequent other events
Showing 10 of 27
Most frequent other events
Event603A: Bexagliflozin Tablets, 20 mg603A: Placebo Tablets603B: Bexagliflozin Tablets, 20 mg603B: Placebo Tablets
PollakiuriaRenal and urinary disorders13/3344/3390/2810/281
NasopharyngitisInfections and infestations12/33411/3394/2812/281
Upper respiratory tract infectionInfections and infestations5/33410/3391/2813/281
PolyuriaRenal and urinary disorders4/3349/3392/2811/281
Urinary tract infectionInfections and infestations7/3347/3396/2816/281
NauseaGastrointestinal disorders7/3345/3391/2813/281
DizzinessNervous system disorders7/3341/3393/2811/281
Oedema peripheralGeneral disorders3/3347/3390/2811/281
HeadacheNervous system disorders4/3347/3391/2812/281
ConstipationGastrointestinal disorders6/3343/3391/2811/281

Baseline characteristics

* To avoid being double-counting of the participants, the number of baseline participants has been entered as "0" for 603B. * Subjects in 603B study had completed 603A study and were qualified to be re-randomized in 603B study.

Age, Continuous
Age, Continuous(years)603A: Bexagliflozin Tablets, 20 mg603 A: Placebo Tablets603B: Bexagliflozin Tablets, 20 mg603B: Placebo TabletsTotal
603A: 0-12 Week Study Period59.4 ± 11.3258.3 ± 12.06——58.9 ± 11.71
603B: 12-36 Week Study Period——59.9 ± 11.3959.2 ± 11.7859.6 ± 11.58
Sex: Female, Male
Sex: Female, Male(Participants)603A: Bexagliflozin Tablets, 20 mg603 A: Placebo Tablets603B: Bexagliflozin Tablets, 20 mg603B: Placebo TabletsTotal
603A: 0-12 Week Study Period — Female12713900266
603A: 0-12 Week Study Period — Male20720000407
603B: 12-36 Week Study Period — Female00110114224
603B: 12-36 Week Study Period — Male00171167338
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)603A: Bexagliflozin Tablets, 20 mg603 A: Placebo Tablets603B: Bexagliflozin Tablets, 20 mg603B: Placebo TabletsTotal
603A: 0-12 Week Study Period — Hispanic or Latino27270054
603A: 0-12 Week Study Period — Not Hispanic or Latino30731200619
603A: 0-12 Week Study Period — Unknown or Not Reported00000
603B: 12-36 Week Study Period — Hispanic or Latino00271946
603B: 12-36 Week Study Period — Not Hispanic or Latino00254262516
603B: 12-36 Week Study Period — Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)603A: Bexagliflozin Tablets, 20 mg603 A: Placebo Tablets603B: Bexagliflozin Tablets, 20 mg603B: Placebo TabletsTotal
603A: 0-12 Week Study Period — American Indian or Alaska Native02002
603A: 0-12 Week Study Period — Asian740011
603A: 0-12 Week Study Period — Native Hawaiian or Other Pacific Islander10001
603A: 0-12 Week Study Period — Black or African American9410400198
603A: 0-12 Week Study Period — White21922000439
603A: 0-12 Week Study Period — More than one race43007
603A: 0-12 Week Study Period — Unknown or Not Reported960015
603B: 12-36 Week Study Period — American Indian or Alaska Native00112
603B: 12-36 Week Study Period — Asian00448
603B: 12-36 Week Study Period — Native Hawaiian or Other Pacific Islander00000
603B: 12-36 Week Study Period — Black or African American009270162
603B: 12-36 Week Study Period — White00178195373
603B: 12-36 Week Study Period — More than one race00246
603B: 12-36 Week Study Period — Unknown or Not Reported004711
Body Mass Index
Body Mass Index(kg/m^2)603A: Bexagliflozin Tablets, 20 mg603 A: Placebo Tablets603B: Bexagliflozin Tablets, 20 mg603B: Placebo TabletsTotal
603A: 0-12 Week Study Period32.29 ± 6.52232.90 ± 6.527——32.59 ± 6.527
603B: 12-36 Week Study Period——32.22 ± 6.95233.17 ± 6.14432.69 ± 6.572
Body Weight at Baseline
Body Weight at Baseline(kg)603A: Bexagliflozin Tablets, 20 mg603 A: Placebo Tablets603B: Bexagliflozin Tablets, 20 mg603B: Placebo TabletsTotal
603A: 0-12 Week Study Period95.36 ± 22.64397.47 ± 22.673——96.42 ± 22.666
603B: 12-36 Week Study Period——95.71 ± 24.32197.55 ± 21.00396.63 ± 22.721
History of Diabetes
History of Diabetes(Participants)603A: Bexagliflozin Tablets, 20 mg603 A: Placebo Tablets603B: Bexagliflozin Tablets, 20 mg603B: Placebo TabletsTotal
603A: 0-12 Week Study Period — Yes8384——167
603A: 0-12 Week Study Period — No251255——506
603B: 12-36 Week Study Period — Yes——7866144
603B: 12-36 Week Study Period — No——203215418
Use of any antihypertension medication
Use of any antihypertension medication(Participants)603A: Bexagliflozin Tablets, 20 mg603 A: Placebo Tablets603B: Bexagliflozin Tablets, 20 mg603B: Placebo TabletsTotal
603A: 0-12 Week Study Period269276——545
603B: 12-36 Week Study Period——233226459

3 further baseline measures are reported on the registry.

08

Study locations

87 sites
  • Clinical Research Site
    Birmingham, Alabama 35205, United States
  • Clinical Research Site
    Birmingham, Alabama 35211, United States
  • Clinical Research Site
    Birmingham, Alabama 35242, United States
  • Clinical Research Site
    Foley, Alabama 36535, United States
  • Clinical Research Site
    Gulf Shores, Alabama 36542, United States
  • Clinical Research Site
    Glendale, Arizona 85306, United States
  • Clinical Research Site
    Mesa, Arizona 85206, United States
  • Clinical Research Site
    Phoenix, Arizona 85020, United States
  • Clinical Research Site
    Tucson, Arizona 85741, United States
  • Clinical Research Site
    Anaheim, California 92801, United States
  • Clinical Research Site
    Bellflower, California 90706, United States
  • Clinical Research Site
    Fair Oaks, California 95628, United States
  • Clinical Research Site
    Fresno, California 93702, United States
  • Clinical Research Site
    Lincoln, California 95648, United States
  • Clinical Research Site
    Los Angeles, California 90057, United States
  • Clinical Research Site
    San Gabriel, California 91776, United States
  • Clinical Research Site
    Santa Rosa, California 95405, United States
  • Clinical Research Site
    Upland, California 91786, United States
  • Clinical Research Site
    Colorado Springs, Colorado 80909, United States
  • Clinical Research Site
    Colorado Springs, Colorado 80918, United States
  • Clinical Research Site
    Denver, Colorado 80246, United States
  • Clinical Research Site
    Golden, Colorado 80401, United States
  • Clinical Research Site
    Stamford, Connecticut 06905, United States
  • Clinical Research Site
    Decatur, Georgia 30030, United States
  • Clinical Research Site
    Decatur, Georgia 30032, United States
  • Clinical Research Site
    Lithonia, Georgia 30058, United States
  • Clinical Research Site
    Chicago, Illinois 60602, United States
  • Clinical Research Site
    Chicago, Illinois 60611, United States
  • Clinical Research Site
    Chicago, Illinois 60616, United States
  • Clinical Research Site
    Avon, Indiana 46123, United States
  • Clinical Research Site
    Evansville, Indiana 47714, United States
  • Clinical Research Site
    Indianapolis, Indiana 46260, United States
  • Clinical Research Site
    Council Bluffs, Iowa 51503, United States
  • Clinical Research Site
    Prairie Village, Kansas 66208, United States
  • Clinical Research Site
    Lexington, Kentucky 40503, United States
  • Clinical Research Site
    Paducah, Kentucky 42003, United States
  • Clinical Research Site
    Versailles, Kentucky 40383, United States
  • Clinical Research Site
    New Orleans, Louisiana 70115, United States
  • Clinical Research Site
    Auburn, Maine 04210, United States
  • Clinical Research Site
    Silver Spring, Maryland 20910, United States
  • Clinical Research Site
    Edina, Minnesota 55435, United States
  • Clinical Research Site
    Bridgeton, Missouri 63044, United States
  • Clinical Research Site
    Saint Louis, Missouri 63141, United States
  • Clinical Research Site
    Henderson, Nevada 89074, United States
  • Clinical Research Site
    Las Vegas, Nevada 89128, United States
  • Clinical Research Site
    Trenton, New Jersey 08611, United States
  • Clinical Research Site
    Albuquerque, New Mexico 87102, United States
  • Clinical Research Site
    Bronx, New York 10455, United States
  • Clinical Research Site
    Brooklyn, New York 11230, United States
  • Clinical Research Site
    Hartsdale, New York 10530, United States
  • Clinical Research Site
    Shelby, North Carolina 28150, United States
  • Clinical Research Site
    Akron, Ohio 44311, United States
  • Clinical Research Site
    Cincinnati, Ohio 45236, United States
  • Clinical Research Site
    Cincinnati, Ohio 45245, United States
  • Clinical Research Site
    Columbus, Ohio 43213, United States
  • Clinical Research Site
    Dayton, Ohio 45439, United States
  • Clinical Research Site
    Dublin, Ohio 43215, United States
  • Clinical Research Site
    Grove City, Ohio 43214, United States
  • Clinical Research Site
    Lyndhurst, Ohio 44124, United States
  • Clinical Research Site
    Edmond, Oklahoma 73034, United States
  • Clinical Research Site
    Oklahoma City, Oklahoma 73119, United States
  • Clinical Research Site
    Portland, Oregon 97239, United States
  • Clinical Research Site
    Altoona, Pennsylvania 16602, United States
  • Clinical Research Site
    Hatboro, Pennsylvania 19040, United States
  • Clinical Research Site
    Lincoln, Rhode Island 02865, United States
  • Clinical Research Site 2
    Anderson, South Carolina 29621, United States
  • Clinical Research Site
    Anderson, South Carolina 29621, United States
  • Clinical Research Site
    Greer, South Carolina 29650, United States
  • Clinical Research Site
    Kingsport, Tennessee 37660, United States
  • Clinical Research Site
    Knoxville, Tennessee 37909, United States
  • Clinical Research Site
    Arlington, Texas 76014, United States
  • Clinical Research Site
    Dallas, Texas 75231, United States
  • Clinical Research Site
    Houston, Texas 77070, United States
  • Clinical Research Site
    Kingwood, Texas 77339, United States
  • Clinical Research Site
    Mesquite, Texas 75143, United States
  • Clinical Research Site
    Plano, Texas 75093, United States
  • Clinical Research Site
    San Antonio, Texas 78229, United States
  • Clinical Research Site
    Tomball, Texas 77375, United States
  • Clinical Research Site
    Layton, Utah 84041, United States
  • Clinical Research Site
    Murray, Utah 84123, United States
  • Clinical Research Site
    West Jordan, Utah 84088, United States
  • Clinical Research Site
    Arlington, Virginia 22207, United States
  • Clinical Research Site
    Burke, Virginia 22015, United States
  • Clinical Research Site
    Charlottesville, Virginia 22911, United States
  • Clinical Research Site
    Danville, Virginia 24541, United States
  • Clinical Research Site
    Manassas, Virginia 20110, United States
  • Clinical Research Site
    Tacoma, Washington 98405, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Nov 2018, 13 months.

Results were first posted in Sep 2021, 2 years 9 months after primary completion. A results delay was requested in Jan 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2017
First posted
May 2, 2018
StartActual
Oct 18, 2017
Primary completionActual
Nov 30, 2018
CompletionActual
Nov 30, 2018
Results delay requested
Jan 31, 2019
Results first posted
Sep 21, 2021
Last update
Sep 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03514641
Lead sponsor
Theracos
Responsible party
Sponsor
First posted
May 2, 2018
Start date
Oct 18, 2017
Primary completion
Nov 30, 2018
Completion
Nov 30, 2018
Results posted
Sep 21, 2021
Last update
Sep 21, 2021

Study contacts

Andrew Allegretti, M.D.
study director · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bexagliflozin

Start the discussion